It effectively inhibits STAT5 signaling in a sub-micromolar concentration and induces tumor regression in chronic myeloid leukemia (CML) xenograft models with good tolerability. Here, STAT5A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.